Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
7.68
-1.39 (-15.33%)
At close: Jun 2, 2025, 4:00 PM
7.93
+0.25 (3.26%)
After-hours: Jun 2, 2025, 7:06 PM EDT

Gyre Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22
Net Income
7.2512.09-92.932.3
Depreciation & Amortization
1.711.591.111.13
Loss (Gain) From Sale of Assets
0.060.073.340
Asset Writedown & Restructuring Costs
--83.1-
Loss (Gain) on Equity Investments
0.060.041.310.25
Stock-Based Compensation
1.330.837.2813.37
Provision & Write-off of Bad Debts
0.370.17-0.060.02
Other Operating Activities
4.014.446.021.4
Change in Accounts Receivable
-3.74-5.260.29-7.92
Change in Inventory
-3.01-2.141.75-0.88
Change in Accounts Payable
-0.21-0.250.19-0.11
Change in Income Taxes
-5.86-2.173-1.34
Change in Other Net Operating Assets
-8.62-13.0511.492.46
Operating Cash Flow
-6.65-3.6425.8910.68
Operating Cash Flow Growth
--142.50%-
Capital Expenditures
-2.21-2.32-8.52-4.99
Sale of Property, Plant & Equipment
0.350.40.66-
Cash Acquisitions
--5.46-
Divestitures
---0.57-
Sale (Purchase) of Intangibles
-1.51-0.81-0.07-0.01
Investment in Securities
-7.33-17.16-16.74-8.82
Investing Cash Flow
-10.7-19.88-19.76-13.81
Issuance of Common Stock
3.452.64--
Other Financing Activities
-0.66-0.54--
Financing Cash Flow
2.792.12.5-
Foreign Exchange Rate Adjustments
-0.18-0.27-0.3-1.89
Net Cash Flow
-14.74-21.78.33-5.03
Free Cash Flow
-8.86-5.9617.385.69
Free Cash Flow Growth
--205.25%-
Free Cash Flow Margin
-8.80%-5.63%15.32%5.56%
Free Cash Flow Per Share
-0.09-0.060.260.07
Cash Income Tax Paid
10.448.526.356.31
Levered Free Cash Flow
-8.55-620.67-
Unlevered Free Cash Flow
-8.55-620.67-
Change in Net Working Capital
14.3915.44-8.85-
Updated May 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q